319 related articles for article (PubMed ID: 17692905)
21. Adjunctive benefits from low-molecular-weight heparins as compared to unfractionated heparin among patients with ST-segment elevation myocardial infarction treated with thrombolysis. A meta-analysis of the randomized trials.
De Luca G; Marino P
Am Heart J; 2007 Dec; 154(6):1085.e1-6. PubMed ID: 18035079
[TBL] [Abstract][Full Text] [Related]
22. [Inhibitory effect of low molecular weight heparin on the secretion of vascular endothelial growth factor by tumor cells in vitro].
Sun Z; Hu ZL; Ning XH; Zhou JF; Shao YJ; Duan JH; Yang XD; Bai CM
Zhonghua Zhong Liu Za Zhi; 2009 Nov; 31(11):826-30. PubMed ID: 20137346
[TBL] [Abstract][Full Text] [Related]
23. Effects of estradiol and progestogens on tumor-necrosis factor-alpha-induced changes of biochemical markers for breast cancer growth and metastasis.
Seeger H; Wallwiener D; Mueck AO
Gynecol Endocrinol; 2008 Oct; 24(10):576-9. PubMed ID: 19012101
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of endothelial cell differentiation and proinflammatory cytokine production during angiogenesis by allyl isothiocyanate and phenyl isothiocyanate.
Thejass P; Kuttan G
Integr Cancer Ther; 2007 Dec; 6(4):389-99. PubMed ID: 18048887
[TBL] [Abstract][Full Text] [Related]
25. Antiangiogenic activity of semisynthetic biotechnological heparins: low-molecular-weight-sulfated Escherichia coli K5 polysaccharide derivatives as fibroblast growth factor antagonists.
Presta M; Oreste P; Zoppetti G; Belleri M; Tanghetti E; Leali D; Urbinati C; Bugatti A; Ronca R; Nicoli S; Moroni E; Stabile H; Camozzi M; Hernandez GA; Mitola S; Dell'Era P; Rusnati M; Ribatti D
Arterioscler Thromb Vasc Biol; 2005 Jan; 25(1):71-6. PubMed ID: 15514208
[TBL] [Abstract][Full Text] [Related]
26. Piper longum inhibits VEGF and proinflammatory cytokines and tumor-induced angiogenesis in C57BL/6 mice.
Sunila ES; Kuttan G
Int Immunopharmacol; 2006 May; 6(5):733-41. PubMed ID: 16546703
[TBL] [Abstract][Full Text] [Related]
27. FGF-8b increases angiogenic capacity and tumor growth of androgen-regulated S115 breast cancer cells.
Mattila MM; Ruohola JK; Valve EM; Tasanen MJ; Seppänen JA; Härkönen PL
Oncogene; 2001 May; 20(22):2791-804. PubMed ID: 11420691
[TBL] [Abstract][Full Text] [Related]
28. Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors.
Coxon A; Bush T; Saffran D; Kaufman S; Belmontes B; Rex K; Hughes P; Caenepeel S; Rottman JB; Tasker A; Patel V; Kendall R; Radinsky R; Polverino A
Clin Cancer Res; 2009 Jan; 15(1):110-8. PubMed ID: 19118038
[TBL] [Abstract][Full Text] [Related]
29. Antiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells.
Pasquier E; Honore S; Pourroy B; Jordan MA; Lehmann M; Briand C; Braguer D
Cancer Res; 2005 Mar; 65(6):2433-40. PubMed ID: 15781659
[TBL] [Abstract][Full Text] [Related]
30. Low-molecular-weight heparin in thrombosis and cancer.
Mousa SA
Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():25-30. PubMed ID: 15085463
[TBL] [Abstract][Full Text] [Related]
31. High antiangiogenic and low anticoagulant efficacy of orally active low molecular weight heparin derivatives.
Park JW; Jeon OC; Kim SK; Al-Hilal TA; Jin SJ; Moon HT; Yang VC; Kim SY; Byun Y
J Control Release; 2010 Dec; 148(3):317-26. PubMed ID: 20869408
[TBL] [Abstract][Full Text] [Related]
32. The effects of growth factors on the proliferation and in vitro angiogenesis of human macular inner choroidal endothelial cells.
Browning AC; Dua HS; Amoaku WM
Br J Ophthalmol; 2008 Jul; 92(7):1003-8. PubMed ID: 18577655
[TBL] [Abstract][Full Text] [Related]
33. [Influence of unfractionated and low-molecular-weight heparin on bone healing: an animal model].
Kock HJ; Werther S; Uhlenkott H; Taeger G
Unfallchirurg; 2002 Sep; 105(9):791-6. PubMed ID: 12232738
[TBL] [Abstract][Full Text] [Related]
34. Anti-cancer properties of low-molecular-weight heparin: preclinical evidence.
Mousa SA; Petersen LJ
Thromb Haemost; 2009 Aug; 102(2):258-67. PubMed ID: 19652876
[TBL] [Abstract][Full Text] [Related]
35. Anti-angiogenic activity of inositol hexaphosphate (IP6).
Vucenik I; Passaniti A; Vitolo MI; Tantivejkul K; Eggleton P; Shamsuddin AM
Carcinogenesis; 2004 Nov; 25(11):2115-23. PubMed ID: 15297368
[TBL] [Abstract][Full Text] [Related]
36. The heparins and cancer: review of clinical trials and biological properties.
Castelli R; Porro F; Tarsia P
Vasc Med; 2004 May; 9(3):205-13. PubMed ID: 15675186
[TBL] [Abstract][Full Text] [Related]
37. Anti-angiogenic effects of ribonucleic acid interference targeting vascular endothelial growth factor and hypoxia-inducible factor-1alpha.
Forooghian F; Das B
Am J Ophthalmol; 2007 Nov; 144(5):761-8. PubMed ID: 17869204
[TBL] [Abstract][Full Text] [Related]
38. Antiangiogenic activity of Diallyl Sulfide (DAS).
Thejass P; Kuttan G
Int Immunopharmacol; 2007 Mar; 7(3):295-305. PubMed ID: 17276887
[TBL] [Abstract][Full Text] [Related]
39. Adrenomedullin stimulates angiogenic response in cultured human vascular endothelial cells: involvement of the vascular endothelial growth factor receptor 2.
Guidolin D; Albertin G; Spinazzi R; Sorato E; Mascarin A; Cavallo D; Antonello M; Ribatti D
Peptides; 2008 Nov; 29(11):2013-23. PubMed ID: 18692535
[TBL] [Abstract][Full Text] [Related]
40. Effect of thalidomide affecting VEGF secretion, cell migration, adhesion and capillary tube formation of human endothelial EA.hy 926 cells.
Komorowski J; Jerczyńska H; Siejka A; Barańska P; Ławnicka H; Pawłowska Z; Stepień H
Life Sci; 2006 Apr; 78(22):2558-63. PubMed ID: 16310808
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
